What happened
Tempus AI agreed in July 2026 to acquire genomics company Personalis for $1.5 billion in stock. One month later, on August 19, 2026, Moderna and Merck announced positive Phase 3 results for mRNA-4157, a personalized mRNA cancer vaccine that uses Personalis's NeXT Personal MRD (minimal residual disease) test to detect trace cancer DNA. The vaccine met its primary endpoint on recurrence-free survival and a secondary endpoint on distant metastasis-free survival in high-risk melanoma patients, marking the first successful late-stage trial of a custom mRNA-based cancer therapy.
Why it matters
Personalis's sequencing platform now underpins a landmark oncology trial, validating the core technology Tempus paid for. Personalis runs 10,384 NeXT Personal tests quarterly (up 199% year over year as of Q2 2026), with four Medicare-covered indications and over 1,400 ordering physicians. For Tempus, MRD is a '$20 billion plus market and one of the fastest growing segments in oncology diagnostics,' according to CEO Eric Lefkofsky. Combined with Tempus's own MRD volume (9,000 tests in Q2 2026, up 38% quarter over quarter), the company now controls a scaled commercial platform behind the same test that just validated a breakthrough cancer treatment. MRD data feeds into Tempus's highest-margin data-licensing business, where pharma partners already pay hundreds of millions annually.
What to watch
Deal close is expected late Q4 2026 or early 2027. Tempus shares jumped 23.91% on August 19, 2026, opening at $49.36 and trading at $61.16. Personalis clinical diagnostic revenue grew 441.6% year over year in Q2 2026, and the company is on track to achieve more than a 500% increase in clinical revenue over the year.
Summaries like this, in your inbox every morning.
Tempus's $1.5 billion acquisition of Personalis, structured as a 100% stock deal announced July 20, 2026, initially drew scrutiny given that Personalis reported only $22.36 million in Q2 2026 revenue. The investment's strategic logic hinges on MRD—minimal residual disease testing—which detects trace cancer DNA in blood and has become central to next-generation oncology. The body of the article explicitly values this market at '$20 billion plus' and notes it is 'one of the fastest growing segments in oncology diagnostics.' Within four weeks of the deal announcement, that thesis received powerful external validation: Moderna and Merck's Phase 3 success on August 19, 2026, proved that the sequencing engine Personalis built could power the first successful late-stage trial of a custom mRNA-based cancer therapy. This validation tightens the strategic fit: Personalis brings clinical scale (10,384 tests in Q2 2026, up 199% year over year, with four Medicare-covered indications), and Tempus contributes distribution and data integration. Combined, they form what amounts to the commercial backbone behind a landmark oncology advance.
The market moved swiftly. Tempus shares jumped 23.91% on August 19, with opening price of $49.36 and intraday high of $61.16. Moderna itself surged 124.14% over the past year and 113.5% year to date, with social media noting a 70% premarket rally on the trial news. Tempus entered the acquisition from a position of strength: Q2 2026 revenue of $382.5 million (up 22% year over year), GAAP net income of $5.6 million, adjusted EBITDA of $8 million, and $820.7 million in cash after a $460 million convertible notes offering. The company raised full-year 2026 revenue guidance to $1.595 billion to $1.605 billion (25% growth), and Q2 data licensing bookings alone totaled roughly $200 million from counterparties including BioNTech, AstraZeneca, Daiichi Sankyo, and Insight Pharmaceuticals. For Tempus, MRD data is not merely a diagnostic asset but a strategic feed into its highest-margin business: data licensing, where pharma partners pay hundreds of millions annually to access proprietary datasets for modeling and research.
Pick your industry and the AI tools you use, and get news related to your work every day.
Free · 30 seconds with Google · unsubscribe anytimeWhat is AIToday? →
Ask AI anything about this article. The AI reads this article, earlier AIToday articles, and Wikipedia, and cites its sources. Q&As are published on this page for other readers too.
Qualcomm trades at 26 times next year's earnings, versus 15 for Nvidia and 22 for Broadcom, even though its st…
SpaceX shares rose more than 5% on Friday after Starship's first trip to Earth orbit and a week of launches, a…
AMD closed at $608.10 on October 9, down 6.36% from its October 6 record close of $649.42, after a Financial T…
The Motley Fool argued SpaceX is the better long-term AI stock than Micron, noting SpaceX's $1.25 billion-per-…
A Motley Fool contributor named Nvidia his top AI stock for 2027, arguing its price could double if it returns…
Hitachi started a service last month using AI models from OpenAI and Anthropic to monitor attacks and restore…
